Acadia, page-842

My notes: not a lot of new information but that's to be expected

• Nuplazid legal challenges still on-going in appealing process. Acadia won the last legal challenge, but the company (who make generics) are appealing. Acadia are confident that the appeal will be upheld based on similar cases where the same company has lost the appeal, and the cases are similar.
• Reiterate that real world experience exceeds clinical trial experience in terms of persistence
• There are a population of patients who have been involved in the initial clinical trials (3+ years) a very small amount (3 patients) has stopped treatment in the last 12 months, suggesting the majority of discontinuations were early on (which backs up the previous point)
• They keep contact with families who discontinue - it is an opportunity. So far there have been some patients who have re-initiated but based on his phrasing I would suggest it is early days and not a large amount.
• Surge of demand on launch - but it does take time to reach more people, HCP, caregivers - real world stories are best method to reach more people